{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:46:57Z","timestamp":1757702817048,"version":"3.40.5"},"reference-count":34,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,4,1]]},"abstract":"<jats:p>Background. The rhesus-human rotavirus reassortant-tetravalent vaccine (RRV-TV) was licensed on August, 31, 1998, and subsequently recommended for routine infant immunizations in the United States. After \u223c1 million doses had been administered, an increase in acute risk of intussusception in vaccinees led to the suspension of the use of RRV-TV and its withdrawal from the market. These postmarketing safety studies focused on a single adverse event (intussusception) and, to minimize the risk of a false-positive finding, accepted only cases that met a strict case definition. Safer rotavirus vaccines are needed to prevent the substantial global morbidity and mortality caused by rotavirus infections; their development and future use may benefit from a better understanding of the postmarketing safety profile of RRV-TV beyond intussusception.<\/jats:p><jats:p>Objective. To characterize more completely the postmarketing surveillance safety profile of RRV-TV by review and analysis of Vaccine Adverse Event Reporting System (VAERS) case reports to better understand 1) whether severe adverse events other than intussusception may have occurred after RRV-TV and 2) the likely scope of gastrointestinal illnesses, of which the previously identified, highly specific intussusception cases may account for just a fraction.<\/jats:p><jats:p>Setting and Participants. Infants vaccinated with RRV-TV and other vaccines in the United States and for whom a report was submitted to VAERS during September 1, 1998, to December 31, 1999.<\/jats:p><jats:p>Methodology. To detect adverse events of interest other than intussusception, we used proportional morbidity analysis to compare the adverse event profile of VAERS reports among infants who received routine vaccines including RRV-TV (after excluding confirmed and suspected intussusception reports) with infants who received identical vaccine combinations but without RRV-TV. Next, to better capture all described diagnoses, signs, and symptoms associated with the suspected adverse events, a set of new codes was developed and assigned to each VAERS report. All 448 nonfatal RRV-TV-associated reports (including intussusception) were recoded manually from the clinical description on the VAERS report and categorized into clinical groups to better describe a spectrum of reported illnesses after the vaccine. Each report was assigned to one of the following hierarchical and mutually exclusive clinical groups: 1) diagnosed intussusception; 2) suspected intussusception; 3) illness consistent with either gastroenteritis or intussusception; 4) gastroenteritis; 5) other gastrointestinal diagnoses (ie, not consistent with intussusception or rotavirus-like gastroenteritis); and 6) nongastrointestinal diagnoses.<\/jats:p><jats:p>Results. Even after excluding intussusception cases, a higher proportion of RRV-TV reports than non-RRV-TV reports included fever and various gastrointestinal symptoms, most notably bloody stool but also vomiting, diarrhea, abdominal pain, gastroenteritis, abnormal stool, and dehydration. Distribution of RRV-TV reports by clinical groups was as follows: diagnosed intussusception (109 [24%], suspected intussusception (36 [8%]), and illness consistent with gastroenteritis or intussusception (33 [7%]), gastroenteritis (101 [22%]), other gastrointestinal diagnoses (10 [2%]), and nongastrointestinal outcomes (159 [35%]). The median time interval between vaccination and illness onset decreased incrementally among the first 4 clinical groups: from 7 days for diagnosed intussusceptions to 3 days for gastroenteritis.<\/jats:p><jats:p>Conclusions. Intussusception and gastroenteritis were the most commonly reported outcomes; however, a substantial number of reports indicate signs and symptoms consistent with either illness, possibly suggestive of a spectrum of gastrointestinal illness(es) related to RRV-TV. Although VAERS data have recognized limitations such as underreporting (that may differ by vaccine) and are nearly always insufficient to prove causality between a vaccine and an adverse event, this safety profile of RRV-TV may aid better understanding of the pathophysiology of intussusception as well as development of future safer rotavirus vaccines.<\/jats:p>","DOI":"10.1542\/peds.113.4.e353","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:53:04Z","timestamp":1092444784000},"page":"e353-e359","source":"Crossref","is-referenced-by-count":33,"title":["An Analysis of Rotavirus Vaccine Reports to the Vaccine Adverse Event Reporting System: More Than Intussusception Alone?"],"prefix":"10.1542","volume":"113","author":[{"given":"Penina","family":"Haber","sequence":"first","affiliation":[{"name":"National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Chen","sequence":"additional","affiliation":[{"name":"National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn R.","family":"Zanardi","sequence":"additional","affiliation":[{"name":"National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina T.","family":"Mootrey","sequence":"additional","affiliation":[{"name":"National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roseanne","family":"English","sequence":"additional","affiliation":[{"name":"National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Miles","family":"Braun","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Office of Biostatistics and Epidemiology, Food and Drug Administration, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the VAERS Working Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2004,4,1]]},"reference":[{"key":"2021121006134241100_R1","doi-asserted-by":"crossref","unstructured":"Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and death caused by rotavirus disease in children. Emerg Infect Dis.2003;9:565\u2013572","DOI":"10.3201\/eid0905.020562"},{"key":"2021121006134241100_R2","doi-asserted-by":"crossref","unstructured":"Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine.1999;17:2207\u20132222","DOI":"10.1016\/S0264-410X(98)00376-4"},{"key":"2021121006134241100_R3","unstructured":"Centers for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep.1999;48(RR-2):1\u201320"},{"key":"2021121006134241100_R4","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Disease. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics.1998;102:1483\u20131491","DOI":"10.1542\/peds.102.6.1483"},{"key":"2021121006134241100_R5","doi-asserted-by":"crossref","unstructured":"Joensuu J, Koskenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J.1998;17:334\u2013340","DOI":"10.1097\/00006454-199804000-00013"},{"key":"2021121006134241100_R6","doi-asserted-by":"crossref","unstructured":"Joensuu J, Koskenniemi E, Pang X-L, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet.1997;350:1205\u20131209","DOI":"10.1016\/S0140-6736(97)05118-0"},{"key":"2021121006134241100_R7","doi-asserted-by":"crossref","unstructured":"Rennels MB, Parashar UD, Holman RC, Le CT, Chang HG, Glass RI. Lack of apparent association between intussusception and wild or vaccine rotavirus infection. Pediatr Infect Dis J.1998;17:924\u2013925","DOI":"10.1097\/00006454-199810000-00018"},{"key":"2021121006134241100_R8","doi-asserted-by":"crossref","unstructured":"Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine.1994;12:542\u2013550","DOI":"10.1016\/0264-410X(94)90315-8"},{"key":"2021121006134241100_R9","unstructured":"Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine-United States, 1998\u20131999. MMWR Morb Mortal Wkly Rep.1999;48:577\u2013581"},{"key":"2021121006134241100_R10","doi-asserted-by":"crossref","unstructured":"Murphy TV, Gargiullo PM, Massoudi MS, et. al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med.2001;344:564\u2013572","DOI":"10.1056\/NEJM200102223440804"},{"key":"2021121006134241100_R11","doi-asserted-by":"crossref","unstructured":"Kramarz P, Frank EK, Destefano F, et. al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J.2001;20:410\u2013416","DOI":"10.1097\/00006454-200104000-00008"},{"key":"2021121006134241100_R12","unstructured":"Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep.1999;48:1007"},{"key":"2021121006134241100_R13","unstructured":"Chen RT. Safety of vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. Third ed. Philadelphia, PA: WB Saunders; 1999:1144\u20131163"},{"key":"2021121006134241100_R14","doi-asserted-by":"crossref","unstructured":"Zanardi LR, Haber P, Mootrey GT, Niu MT, Wharton M; the VAERS Working Group. Intussusception among recipients of rotavirus vaccine: reports to the Vaccine Adverse Event Reporting System. Pediatrics.2001;107(6). Available at: www.pediatrics.org\/cgi\/content\/full\/107\/6\/e97","DOI":"10.1542\/peds.107.6.e97"},{"key":"2021121006134241100_R15","doi-asserted-by":"crossref","unstructured":"Teutsch SM, Churchill RE, eds. Principles and Practice of Public Health Surveillance. Second ed. New York, NY: Oxford University Press; 2000","DOI":"10.1093\/oso\/9780195138276.001.0001"},{"key":"2021121006134241100_R16","unstructured":"Ellenberg SS, Chen RT. The complicated task of monitoring vaccine safety. Public Health Rep.1997;112:10\u201321"},{"key":"2021121006134241100_R17","doi-asserted-by":"crossref","unstructured":"Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine.1999;17:2908\u20132917","DOI":"10.1016\/S0264-410X(99)00132-2"},{"key":"2021121006134241100_R18","doi-asserted-by":"crossref","unstructured":"Rosenthal S, Chen RT. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health.1995;85:1706\u20131709","DOI":"10.2105\/AJPH.85.12.1706"},{"key":"2021121006134241100_R19","doi-asserted-by":"crossref","unstructured":"Braun MM, Ellenberg SS. Descriptive epidemiology of adverse events after immunization: reports to the Vaccine Adverse Event Reporting System (VAERS), 1991\u20131994. J Pediatr.1997;131:529\u2013535","DOI":"10.1016\/S0022-3476(97)70056-8"},{"key":"2021121006134241100_R20","unstructured":"US Food and Drug Administration. COSTART: Coding Symbols for a Thesaurus of Adverse Reaction Terms. Third ed. Rockville, MD: US Food and Drug Administration; 1989"},{"key":"2021121006134241100_R21","unstructured":"US Food and Drug Administration. Postmarketing reporting of adverse experiences. 21 CFR parts 600.80. Fed Regist.1997;62:52252\u201352253"},{"key":"2021121006134241100_R22","doi-asserted-by":"crossref","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf.2001;10:483\u2013486","DOI":"10.1002\/pds.677"},{"key":"2021121006134241100_R23","doi-asserted-by":"crossref","unstructured":"Evans SJW. Pharmacovigilance: a science or fielding emergencies?Stat Med.2000;19:3199\u20133209","DOI":"10.1002\/1097-0258(20001215)19:23<3199::AID-SIM621>3.0.CO;2-Q"},{"key":"2021121006134241100_R24","doi-asserted-by":"crossref","unstructured":"Finney DJ. Systematic signaling of adverse reactions to drugs. Methods Inf Med.1974;13:1\u201310","DOI":"10.1055\/s-0038-1636131"},{"key":"2021121006134241100_R25","doi-asserted-by":"crossref","unstructured":"Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunizations. JAMA.1997;278:1176\u20131178","DOI":"10.1001\/jama.278.14.1176"},{"key":"2021121006134241100_R26","doi-asserted-by":"crossref","unstructured":"Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992\u20131993 and 1993\u20131994 influenza vaccines. N Engl J Med.1998;339:1797\u20131802","DOI":"10.1056\/NEJM199812173392501"},{"key":"2021121006134241100_R27","doi-asserted-by":"crossref","unstructured":"Verstraeten T, Baughman AL, Cadwell B, Zanardi L, Haber P, Chen RT. Enhancing the Vaccine Adverse Event Reporting System: a capture-recapture analysis of intussusception after rotavirus vaccination. Am J Epidemiol.2001;154:1006\u20131012","DOI":"10.1093\/aje\/154.11.1006"},{"key":"2021121006134241100_R28","unstructured":"Weber JC. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances in Inflammation Research. New York, NY: Raven Press; 1984:1\u20137"},{"key":"2021121006134241100_R29","doi-asserted-by":"crossref","unstructured":"Smith PJ, Schwartz B, Mokdad A, Bloch AB, McCauley M, Murphy TV. The first oral rotavirus vaccine, 1998\u20131999: estimates of uptake from the National Immunization Survey. Public Health Rep.2003;118:134\u2013143","DOI":"10.1093\/phr\/118.2.134"},{"key":"2021121006134241100_R30","doi-asserted-by":"crossref","unstructured":"Mathews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2000 period linked birth\/infant death data set. Natl Vital Stat Rep.2002;50:1\u201328","DOI":"10.1037\/e558952006-001"},{"key":"2021121006134241100_R31","doi-asserted-by":"crossref","unstructured":"Kornecki A, Daneman A, Navarro O, Connolly B, Manson D, Alton DJ. Spontaneous reduction of intussusception: clinical spectrum, management and outcome. Pediatr Radiol.2000;30:58\u201363","DOI":"10.1007\/s002470050015"},{"key":"2021121006134241100_R32","doi-asserted-by":"crossref","unstructured":"Swischuk LE, John SD, Swischuk PN. Spontaneous reduction of intussusception: verification with US. Radiology.1994;192:269\u2013271","DOI":"10.1148\/radiology.192.1.8208951"},{"key":"2021121006134241100_R33","doi-asserted-by":"crossref","unstructured":"Albet MJ, Faruque ASG, Faruque SM, Sack RB, Mahalanabis D. Case-control study of enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. J Clin Microbiol.1999;37:3458\u20133464","DOI":"10.1128\/JCM.37.11.3458-3464.1999"},{"key":"2021121006134241100_R34","doi-asserted-by":"crossref","unstructured":"Chang EJ, Zangwill KM, Lee H, Ward JI. Lack of association between rotavirus infection and intussusception: implications for use of attenuated rotavirus vaccines. Pediatr Infect Dis J.2002;21:97\u2013102","DOI":"10.1097\/00006454-200202000-00003"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/113\/4\/e353\/1013233\/zpe0040400e353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/113\/4\/e353\/1013233\/zpe0040400e353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T05:23:25Z","timestamp":1705209805000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/113\/4\/e353\/63929\/An-Analysis-of-Rotavirus-Vaccine-Reports-to-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2004,4,1]]},"published-print":{"date-parts":[[2004,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.113.4.e353","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2004,4,1]]}}}